Clinical Trial Update: A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

View source ↗

Summary

The study evaluated real-world current standards of care for relapsed/refractory multiple myeloma patients who have received at least three prior lines includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Multiple Myeloma | Status: COMPLETED